References

  1. Abrami L, Reig N, van der Goot FG. Anthrax toxin: the long and winding road that leads to the kill. Trends Microbiol. 2005;13(2):72–8. [PubMed: 15680766]
  2. Adamovicz J, Andrews G. Plague vaccines: Retrospective analysis and future developments. In: Lindler L, editor. Biological Weapons Defense: Infectious Diseases and Counterbioterrorism. 2nd ed. Totowa, NJ: Human Press, Inc; 2005.
  3. Advance Research Technologies, C and GE Healthcare. eXplore Optix System. [accessed September 2005]. Available online at http://www.art.ca/en/products/sami_system.html.
  4. Albrink WS, Goodlow RJ. Experimental inhalation anthrax in the chimpanzee. Am J Pathol. 1959;35:1055–65. [PMC free article: PMC1934839] [PubMed: 13792450]
  5. American Conference of Governmental Industrial Hygienists. 2005 TLVs® and BEIs®. Cincinnati, OH: American Conference of Governmental Industrial Hygienists; 2005.
  6. Beck SE, Laube BL, Barberena CI, Fischer AC, Adams RJ, Chesnut K, Flotte TR, Guggino WB. Deposition and expression of aerosolized rAAV vectors in the lungs of rhesus macaques. Mol Ther. 2002;6(4):546–54. [PubMed: 12387250]
  7. Becquemin MH, Swift DL, Bouchikhi A, Roy M, Teillac A. Particle deposition and resistance in the noses of adults and children. Eur Respir J. 1991;4(6):694–702. [PubMed: 1889496]
  8. Birchall A, Baily MR, James AC. LUDEP: a lung dose evaluation program. Radn Protn Doism. 1991;38:167–74.
  9. Brain JD, Knudson DE, Sorokin SP, Davis MA. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation. Environ Res. 1976;11(1):13–33. [PubMed: 1253768]
  10. Brey RN. Molecular basis for improved anthrax vaccines. Adv Drug Deliv Rev. 2005;57(9):1266–92. [PubMed: 15935874]
  11. Brittingham KC, Ruthel G, Panchal RG, Fuller CL, Ribot WJ, Hoover TA, Young HA, Anderson AO, Bavari S. Dendritic cells endocytose Bacillus anthracis spores: implications for anthrax pathogenesis. J Immunol. 2005;174(9):5545–52. [PubMed: 15843553]
  12. Brown JS, Wilson WE, Grant LD. Dosimetric comparisons of particle deposition and retention in rats and humans. Inhal Toxicol. 2005;17(7-8):355–85. [PubMed: 16020034]
  13. Biological Weapons Convention (BWC) List of States Parties to the Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons and on Their Destruction as at December 2004. 2004. [accessed September 2005]. Available online at http://www.opbw.org/new_process/msp2004/BWC_MSP_2004_Inf.2_E.pdf.
  14. Burn JH, Finney DJ, Goodwin LG. 2 ed. London: Oxford University Press; 1950. Biological Standardization.
  15. Casadevall A, Pirofski LA. Host-pathogen interactions: redefining the basic concepts of virulence and pathogenicity. Infect Immun. 1999;67(8):3703–13. [PMC free article: PMC96643] [PubMed: 10417127]
  16. Cassell GJ. Biological Threats and Terrorism: Assessing the Science and Response Capabilities: Workshop Summary. Washington, DC: National Academy Press; 2002. Countermeasures to biological threats: the challenge of drug development. National Research Council. [PubMed: 22787686]
  17. Centers for Disease Control (CDC), National Institutes of Health (NIH), Department of Health and Human Services (DHHS) Biosafety in Microbiological and Biomedical Laboratories (BMBL) 4 ed. Washington, DC: Government Printing Office; 1999.
  18. Chen D-R, Pui DYH, Kaufman SL. Electrospraying of conducting liquids for monodisperse aerosol generation in the 4 nm to 1.8 μm diameter range. J Aerosol Sci. 1995;26(6):963–77.
  19. Contag CH, Bachmann MH. Advances in in vivo bioluminescence imaging of gene expression. Annu Rev Biomed Eng. 2002;4:235–60. [PubMed: 12117758]
  20. Department of Health and Human Services (DHHS) Budget in Brief -Fiscal Year 2006. 2005. [accessed September 28, 2005]. Available online at http://www.hhs.gov/budget/06budget/FY2006BudgetinBrief.pdf.
  21. Dixon WJ, Mood AM. A method for obtaining and analyzing sensitivity data. J Am Stat Assoc. 1948;43:109–126.
  22. Dunbar CA, Hickey AJ, Holzner P. Dispersion and characterization of pharmaceutical dry powder aerosols. KONA. 1998;16:7–45.
  23. Environmental Protection Agency (EPA) Air Quality Criteria for Particulate Matter. III. Washington, DC: 1996.
  24. Ezzell JW, Ivins BE, Leppla SH. Immunoelectrophoretic analysis, toxicity, and kinetics of in vitro production of the protective antigen and lethal factor components of Bacillus anthracis toxin. Infect Immun. 1984;45(3):761–7. [PMC free article: PMC263363] [PubMed: 6432700]
  25. Food and Drug Administration (FDA) Draft Guidance for Industry: Inhalational Anthrax (Post-exposure) - Developing Antimicrobial Drugs. 2002. [accessed September 2005]. Available online at http://www.fda.gov/cder/guidance/4848dft.htm.
  26. Feder PI, Hobson DW, Olson CT, Joiner RL, Matthews MC. Stagewise, adaptive dose allocation for quantal response dose-response studies. Neurosci Biobehav Rev. 1991a;15(1):109–14. [PubMed: 2052182]
  27. Feder PI, Olson CT, Hobson DW, Matthews MC. Statistical analysis of dose-response experiments by maximum likelihood analysis and iteratively reweighted nonlinear least squares techniques. Drug Inf J. 1991b;25:323–34.
  28. Feder PI, Olson CT, Hobson DW, Matthews MC, Joiner RL. Stagewise, group sequential experimental designs for quantal responses. one-sample and two-sample comparisons. Neurosci Biobehav Rev. 1991c;15(1):129–33. [PubMed: 2052185]
  29. Fellows PF, Linscott MK, Ivins BE, Pitt ML, Rossi CA, Gibbs PH, Friedlander AM. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine. 2001;19(23-24):3241–7. [PubMed: 11312020]
  30. Flick-Smith HC, Waters EL, Walker NJ, Miller J, Stagg AJ, Green M, Williamson ED. Mouse model characterisation for anthrax vaccine development: Comparison of one inbred and one outbred mouse strain. Microb Pathog. 2005;38(1):33–40. [PubMed: 15652293]
  31. Foster WM, Walters DM, Longphre M, Macri K, Miller LM. Methodology for the measurement of mucociliary function in the mouse by scintigraphy. J Appl Physiol. 2001;90(3):1111–7. [PubMed: 11181627]
  32. Friedlander AM, Welkos SL, Ezzell JW, Worsham PL, Rose KJ, Ivins BE, Lowe JR, Howe GB, Mikesell P, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis. 1993;167:1239–42. [PubMed: 8486963]
  33. Fritz DL, Jaax NK, Lawrence WB, Davis KJ, Pitt MLM, Ezzell JW, Friedlander AM. Pathology of experimental inhalation anthrax in the rhesus monkey. Lab Invest. 1995;73(5):691–702. [PubMed: 7474943]
  34. Gelfand AS, Larsen GL, Loader JE, Graves JP, Fan LL, Colasurdo GN. Effect of aspiration of milk on mechanisms of neural control in the airways of developing rabbits. Pediatr Pulmonol. 1997;23(3):198–204. [PubMed: 9094728]
  35. Glassman HN. Discussion: industrial inhalation anthrax. Bacteriol Rev. 1966;30(3):657–9. [PMC free article: PMC378259] [PubMed: 16350199]
  36. Hafner K, Lyon M. New York, NY: Simon & Schuster; 1996. Where Wizards Stay Up Late: The Origins of the Internet.
  37. Haigwood NL. Predictive value of primate models for AIDS. AIDS Rev. 2004;6(4):187–98. [PubMed: 15700617]
  38. Harkema JR. Comparative pathology of the nasal mucosa in laboratory animals exposed to inhaled irritants. Environ Health Perspect. 1990;85:231–8. [PMC free article: PMC1568334] [PubMed: 2116960]
  39. Hartings JM, Roy CJ. The automated bioaerosol exposure system: preclinical platform development and a respiratory dosimetry application with nonhuman primates. J Pharmacol Toxicol Methods. 2004;49(1):39–55. [PubMed: 14670693]
  40. Henderson DW. An apparatus for the study of airborne infection. J Hyg (Lond) 1952;50:53–68. [PMC free article: PMC2235137] [PubMed: 14908062]
  41. Hinds WC. Aerosol Technology: Properties, behavior, and measurements of airborne particles. 2 ed. New York: Wiley-Interscience; 1999.
  42. Hinds WC, Kennedy NJ. An ion generator for neutralizing concentrated aerosols. Aerosol Sci Technol. 2000;32:214–20.
  43. Hu SL. Non-human primate models for AIDS vaccine research. Curr Drug Targets Infect Disord. 2005;5(2):193–201. [PMC free article: PMC1488817] [PubMed: 15975024]
  44. International Commission on Radiological Protection (ICRP) Human respiratory tract model for radiological protection. Ann ICRP. 1995;(3-4):iii.
  45. Ivins BE, Pitt ML, Fellows PF, Farchaus JW, Benner GE, Waag DM, Little SF, Anderson GW Jr, Gibbs PH, Friedlander AM. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine. 1998;16(11-12):1141–8. [PubMed: 9682372]
  46. Jahrling P, Hensley L, Martinez M, LeDuc J, Rubins K, Relman D, Huggins J. Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc Natl Acad Sci USA. 2004;101(42):15496–200. [PMC free article: PMC523454] [PubMed: 15477589]
  47. Jarabek AM. The application of dosimetry models to identify key processes and parameters for default dose-response assessment approaches. Toxicol Lett. 1995;79(1-3):171–84. [PubMed: 7570654]
  48. Jarabek AM, Asgharian B, Miller FJ. Dosimetric adjustments for interspecies extrapolation of inhaled poorly soluble particles (PSP) Inhal Toxicol. 2005;17(7-8):317–34. [PubMed: 16020031]
  49. Jay SJ, Johanson WG Jr, Pierce AK, Reisch JS. Determinants of lung bacterial clearance in normal mice. J Clin Invest. 1976;57(4):811–7. [PMC free article: PMC436723] [PubMed: 7575]
  50. Ji JH, Bae GN, Hwang J. Characteristics of aerosol charge neutralizers for highly charged particles. J Aerosol Sci. 2004;35:1347–58.
  51. Johnson E, Jaax N, White J, Jahrling P. Lethal experimental infections of rhesus monkeys by aerosolized ebola virus. Int J Exp Pathol. 1995;76(4):227–36. [PMC free article: PMC1997182] [PubMed: 7547435]
  52. Johnston JB, Olson ME, Rud EW, Power C. Xenoinfection of nonhuman primates by feline immunodeficiency virus. Curr Biol. 2001;11(14):1109–13. [PubMed: 11509233]
  53. Jones MN, Beedham RJ, Turnbull PCB, Fitzgeorge RB, Manchee RJ. Efficacy of the UK human anthrax vaccine in guinea pig aerosolised spores of Bacillus anthracis. Salisbury Med Bull. 1985;87:123–4.
  54. Kelly JT, Bobbitt CM, Asgharian B. In vivo measurement of fine and coarse aerosol deposition in the nasal airways of female long-evans rats. Toxicol Sci. 2001;64(2):253–8. [PubMed: 11719708]
  55. Kennedy RC, Shearer MH, Hildebrand W. Nonhuman primate models to evaluate vaccine safety and immunogenicity. Vaccine. 1997;15(8):903–8. [PubMed: 9234544]
  56. Kiratisin P, Fukuda CD, Wong A, Stock F, Preuss JC, Ediger L, Brahmbhatt TN, Fischer SH, Fedorko DP, Witebsky FG, et al. Large-scale screening of nasal swabs for Bacillus anthracis: Descriptive summary and discussion of the national institutes of health's experience. J Clin Microbiol. 2002;40(8):3012–6. [PMC free article: PMC120640] [PubMed: 12149367]
  57. Lalor CB, Hickey AJ. Generation and characterization of aerosols for drug delivery to the lungs. In: Adjei A, Gupta PK, editors. Inhalation and Delivery of Therapeutic Peptides and Proteins. New York: Marcel Dekker; 1997. pp. 235–76.
  58. Larsen GL, Loader J, Nguyen DD, Colasurdo GN. Mechanisms of cholinergic dysfunction in rabbits following recurrent aspiration of cow's milk. Pediatr Pulmonol. 2001;32(6):409–17. [PubMed: 11747243]
  59. Larson EW, Dominik JW, Slone TW. Aerosol stability and respiratory infectivity of Japanese B encephalitis virus. Infect Immun. 1980;30(2):397–401. [PMC free article: PMC551325] [PubMed: 6254888]
  60. Laube BL. The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care. 2005;50(9):1161–76. [PubMed: 16122400]
  61. Leach LJ, Spiegl CJ, Wilson RH, Sylvester GE, Lauterbach KE. A multiple chamber exposure unit designed for chronic inhalation studies. Am Ind Hyg Assoc J. 1959;20(1):13–22. [PubMed: 13626827]
  62. Levy JA. The value of primate models for studying human immunodeficiency virus pathogenesis. J Med Primatol. 1996;25(3):163–74. [PubMed: 8892037]
  63. Little SF, Ivins BE, Fellows PF, Pitt ML, Norris SL, Andrews GP. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine. 2004;22(3-4):422–30. [PubMed: 14670324]
  64. Lodge JP, Chan TL. Cascade Impactor: Sampling and Data Analysis; American Conference of Government Industrial Hygienists; Akron, OH. 1986.
  65. Louveau C, Descroix D, Garnier L, Delamanche I, Chavarot P, Ramisse F, Marchal G, Vergnaud G. A nose-only apparatus for airborne delivery of mycobacterium tuberculosis to mice: calibration of biological parameters. Microbes Infect. 2005;7(3):457–66. [PubMed: 15792637]
  66. Mainelis G, Berry D, An HR, Yao M, Devoe K, Fennell DE, Jaeger R. Design and performance of a single-pass bubbling bioaerosol generator. Atmos Environ. 2005;39(19):3521–33.
  67. Manchester M, Rall GF. Model systems: transgenic mouse models for measles pathogenesis. Trends Microbiol. 2001;9(1):19–23. [PubMed: 11166238]
  68. Martonen TB, Zhang Z, Yue G, Musante CJ. Fine particle deposition within human nasal airways. Inhal Toxicol. 2003;15(4):283–303. [PubMed: 12635000]
  69. May KR. The Collison nebulizer, description, performance, and applications. J Aerosol Sci. 1973;4:235–43.
  70. McNeil DG. Drug tested in gulf war is approved for troops. The New York Times; A. 2003 Feb 6;23:1.
  71. Méry S, Gross EA, Joyner DR, Godo M, Morgan KT. Nasal diagrams: a tool for recording the distribution of nasal lesions in rats and mice. Toxicol Pathol. 1994;22(4):353–72. [PubMed: 7817125]
  72. Miller LM, Foster WM, Dambach DM, Doebler D, McKinnon M, Killar L, Longphre M. A murine model of cigarette smoke-induced pulmonary inflammation using intranasally administered smoke-conditioned medium. Exp Lung Res. 2002;28(6):435–55. [PubMed: 12217211]
  73. Moberg LJ, Sugiyama H. The rat as an animal model for infant botulism. Infect Immun. 1980;29(2):819–21. [PMC free article: PMC551196] [PubMed: 7011988]
  74. Morgan KT, Monticello TM. Airflow, gas deposition, and lesion distribution in the nasal passages. Environ Health Perspect. 1990;85:209–18. [PMC free article: PMC1568327] [PubMed: 2200663]
  75. Moss O, Cheng Y. Atmospheres: particles and droplets. In: Henderson R, McClellan R, editors. Concepts in Inhalation Toxicology. 2nd ed. Washington, DC: Taylor & Francis; 1995a. pp. 91–125.
  76. Moss O, Cheng Y. Inhalation Exposure Systems. In: McClellan R, Henderson R, editors. Concepts in Inhalation Toxicology. Washington, DC: Taylor & Francis; 1995b.
  77. National Council on Radiation Protection and Measurements (NCRP) Report 125. Bethesda, MD: NCRP; 1997.
  78. National Institute of Allergy and Infectious Diseases (NIAID) Washington, DC: Government Printing Office; 2002. NIH Publication No. 03-5306.
  79. Nicas M, Nazaroff WW, Hubbard A. Toward understanding the risk of secondary airborne infection: emission of respirable pathogens. J Occupa Environ Hyg. 2005;2(3):143–54. [PubMed: 15764538]
  80. National Research Council (NRC) The Psychological Well-Being of Nonhuman Primates. Washington, DC: National Academy Press; 1998.
  81. Oldham MJ, Phalen RF. Dosimetry implications of upper tracheobronchial airway anatomy in two mouse varieties. Anat Rec. 2002;268(1):59–65. [PubMed: 12209565]
  82. Patterson JL, Carrion R Jr. Demand for nonhuman primate resources in the age of biodefense. ILAR Journal. 2005;46(1):15–22. [PubMed: 15644560]
  83. Phalen RF. Establishing and controlling exposure environments. In: Phalen RF, editor. Inhalation Studies: Foundations and Techniques. Boca Raton, FL: CRC Press; 1984. pp. 88–9.pp. 107–115.
  84. Phalen RF, Mannix RC, Drew RT. Inhalation exposure methodology. Environ Health Perspect. 1984;56:23–34. [PMC free article: PMC1568202] [PubMed: 6383799]
  85. Phipps AJ, Premanandan C, Barnewall RE, Lairmore MD. Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines. Microbiol Mol Biol Rev. 2004;68(4):617–29. [PMC free article: PMC539006] [PubMed: 15590776]
  86. Pitt ML, Little SF, Ivins BE, Fellows P, Barth J, Hewetson J, Gibbs P, Dertzbaugh M, Friedlander AM. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine. 2001;19(32):4768–73. [PubMed: 11535328]
  87. Pitt MLM. Biology of Appropriate Dose in Animals vs. Humans; Workshop of the Committee on Animal Models for Testing Interventions Against Aerosolized Bioterrorism Agents; Washington, DC. 2005.
  88. Raabe OG, Al-Bagati MA, Teague SV, Rasolt A. Regional deposition of inhaled monodisperse coarse and fine aerosol particles in small laboratory animals. Ann Occup Hyg. 1988;32(Suppl. 1):53–63.
  89. Raabe OG, Yeh H-C, Newton GJ, Phalen RF, Velasquez DJ. Deposition of inhaled monodisperse aerosols in small rodents. In: Walton WH, McGovern B, editors. Inhaled Particles. 4th ed. New York: Pergammon Press; 1977. pp. 3–33.
  90. Robinson J, Beattie G. International Perspectives: The future of nonhuman primate resources. Washington, DC: National Academy Press; 2003. Nonhuman primate resource needs: a moving target. NRC.
  91. Rotz LD, Khan AS, Lillibridge SR, Ostroff SM, Hughes JM. Public health assessment of potential biological terrorism agents. 2002;8 [PMC free article: PMC2732458] [PubMed: 11897082]
  92. Roy CJ, Hale M, Hartings JM, Pitt L, Duniho S. Impact of inhalation exposure modality and particle size on the respiratory deposition of Ricin in Balb/C Mice. Inhal Toxicol. 2003;15(6):619–38. [PubMed: 12692733]
  93. Rubsamen R. Novel aerosol peptide drug delivery systems. In: Adjei A, Gupta PK, editors. Inhalation Delivery of Therapeutic Peptides and Proteins. New York: Marcel Dekker; 1997.
  94. Schlesinger RB. Comparative deposition of inhaled aerosols in experimental animals and humans: a review. J Toxicol Environ Health. 1985;15(2):197–214. [PubMed: 3892021]
  95. Shafazand S, Doyle R, Ruoss S, Weinacker A, Raffin TA. Inhalational anthrax: epidemiology, diagnosis, and management. Chest. 1999;116(5):1369–76. [PubMed: 10559102]
  96. Sibal LR, Samson KJ. Nonhuman primates: a critical role in current disease research. ILAR Journal. 2001;42(2):74–84. [PubMed: 11406709]
  97. Snipes MB. Biokinetics of inhaled radionuclides. In: Raabe OG, editor. Internal Radiation Dosimetry. Madison, WI: Health Physics Society; 1994.
  98. Steinbach WJ, Benjamin DK Jr, Trasi SA, Miller JL, Schell WA, Zaas AK, Foster WM, Perfect JR. Value of an inhalational model of invasive aspergillosis. Med Mycol. 2004;42(5):417–25. [PubMed: 15552643]
  99. Stober W, McClellan RO. Pulmonary retention and clearance of inhaled biopersistent aerosol particles: data-reducing interpolation models and models of physiologically based systems—a review of recent progress and remaining problems. Crit Rev Toxicol. 1997;27(6):539–98. [PubMed: 9408732]
  100. Subramaniam RP, Asgharian B, Freijer JI, Miller FJ, Anjilvel S. Analysis of lobar differences in particle deposition in the human lung. Inhal Toxicol. 2003;15(1):1–21. [PubMed: 12476357]
  101. Swift DL. Aerosol characterization and generation. In: Moren F, Dolovich MB, Newhouse MT, Newman SP, editors. Aerosols in Medicine-Principles, Diagnosis, and Therapy. 2nd ed. Amsterdam, The Netherlands: Elsevier Science Publishers; 1993. p. 78.
  102. Tyler WS. Comparative subgross anatomy of lungs: pleuras, interlobular septa, and distal airways. Am Rev Respir Dis. 1983;128(2 Pt 2):S32–6. [PubMed: 6881704]
  103. Taylor E. Strengthening the biological weapons convention: Illusory benefits and nasty side effects. Policy Anal. 1999;355:1–16.
  104. Toth LA. Defining the moribund condition as an experimental endpoint for animal research. ILAR Journal. 2000;41(2):72–9. [PubMed: 11406700]
  105. Ugwoke MI, Verbeke N, Kinget R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J Pharm Pharmacol. 2001;53(1):3–21. [PubMed: 11206189]
  106. Vasconcelos D, Barnewall R, Babin M, Hunt R, Estep J, Nielsen C, Carnes R, Carney J. Pathology of inhalation anthrax in cynomolgus monkeys (Macaca fascicularis) Lab Invest. 2003;83(8):1201–9. [PubMed: 12920249]
  107. Vincent JH. Aerosol sampling in workplaces. In: Vincent JH, editor. Aerosol Science for Industrial Hygienists. Tarrytown, NY: Elsevier Science, Inc; 1995. pp. 238–303.
  108. Warwick R, Williams PL, editors. Gray's Anatomy. Philadelphia: W.B. Saunders Company; 1973.
  109. Weibel ER. Morphometry of the Human Lung. Berlin: Springer-Verlag; 1963.
  110. Welkos S, Pitt ML, Martinez M, Friedlander A, Vogel P, Tammariello R. Determination of the virulence of the pigmentation-deficient and pigmentation-/plasminogen activator-deficient strains of Yersinia pestis in non-human primate and mouse models of pneumonic plague. Vaccine. 2002;20(17-18):2206–14. [PubMed: 12009274]
  111. Welkos SL, Keener TJ, Gibbs PH. Differences in susceptibility of inbred mice to Bacillus anthracis. Infect Immun. 1986;51(3):795–800. [PMC free article: PMC260968] [PubMed: 3081444]
  112. Wolff RK. Experimental investigation of deposition and fate of particles: animal models and interspecies differences. In: Marijnissen JCM, Gradon L, editors. Aerosol Inhalation: Recent Research Frontiers. Norwell, MA: Kluwer Academic Publishers; 1996. pp. 247–63.
  113. Zaucha GM, Jahrling PB, Geisbert TW, Swearengen JR, Hensley L. The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis) Lab Invest. 2001;81(12):1581–600. [PubMed: 11742030]
  114. Zaucha GM, Pitt LM, Estep J, Ivins BE, Friedlander AM. The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch Pathol Lab Med. 1998;122(11):982–92. [PubMed: 9822127]